Deutsche Bank raised the firm’s price target on Elevance Health to $575 from $571 and keeps a Buy rating on the shares post the Q1 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ELV:
- Elevance Health price target lowered to $564 from $577 at TD Cowen
- Elevance Health reports Medical enrollment of 48.1M members on March 31
- Elevance Health raises FY23 adjusted EPS view to greater than $32.70 per share
- Elevance Health reports Q1 adjusted EPS 9.46, consensus $9.26
- Elevance Health, Inc. (ELV) Q1 Earnings Cheat Sheet
